Qorvo's declining ROCE and stagnant capital employed may suggest a mature business facing new competition or smaller margins. Despite concerning fundamentals, the stock's strong performance with a 63% return over the last five years indicates investor optimism. However, these trends may not bode well for long-term performance.
The growth outlook of Qorvo, coupled with its current undervaluation, makes it a potential buy. The undervaluation is attributed not only to its future expectations but also its financial health.
Qorvo executives express confidence in Luxshare's manufacturing competency and anticipate the partnership will help reduce capital intensity, support long-term gross margin objectives, and ensure continuity for their customers in China.
Morning Movers Gapping up $开利全球(CARR.US)$Shares popped nearly 6% following the announcement that Carrier agreed to sell its Global Access Solutions Business to Honeywell for $4.95 billion in cash.$霍尼韦尔(HON.US)$'s stock slipped 2.4%. $第一太阳能(FSLR.US)$The solar stock rallied 3.2% after being upgraded to overweight from equal weight by Morgan Stanley. The bank said it sees a number of drivers that can pus...
Qorvo's declining share price and EPS loss depict dwindling investor trust. However, recent sell-off might be a chance considering a long-term growth trend.
Despite the revenue contraction and gross margin decrease, Qorvo's performance is considered strong, with better-than-expected results and strong improvement in inventory levels. However, considering Qorvo's valuation and recent quarter changes, further research is suggested before investing.
Pre-Market Stock Movers Gapping up $Moderna(MRNA.US)$ (Shares added 1.6% after the biotech company released its second-quarter results. Despite posting a quarterly loss and drop in revenue, Moderna raised its full-year outlook for its Covid vaccine, its only marketable product.) $Qorvo(QRVO.US)$ (The stock rallied 6.8% after the company beat analyst expectations on top and bottom lines in the second quarter. Manage...
Qorvo股票讨论区
2015年上市,主要做射频和电源半导体业务,51%的市场在美国,当前价格112.17。
5年来营收前4年增长,2023年萎缩23.2%,平均增速3.7%,营业利润2022年达到高点后在2023年受毛利率大幅下滑和费用增长影响大幅萎缩85.1%,净利润萎缩到1亿。2023年利息费用0.68亿。毛利率前4年从38.7%提升到49.2%,2023年大幅下滑到36.3%。
2024前3季度营收萎缩3.7%,营业利润大幅萎缩83.4%,净利润转为亏损0.73亿。
目前市盈率112,市盈率TTM亏损,5年平均净利4.7亿对应市盈率为23,按周期股来看估值也不低,暂时缺乏吸引力。
Gapping up
$开利全球(CARR.US)$ Shares popped nearly 6% following the announcement that Carrier agreed to sell its Global Access Solutions Business to Honeywell for $4.95 billion in cash. $霍尼韦尔(HON.US)$ 's stock slipped 2.4%.
$第一太阳能(FSLR.US)$ The solar stock rallied 3.2% after being upgraded to overweight from equal weight by Morgan Stanley. The bank said it sees a number of drivers that can pus...
$凌云半导体(CRUS.US)$ Kioxia Japan $德州仪器(TXN.US)$ $恩智浦(NXPI.US)$ $博通(AVGO.US)$ Skhynix Korea $RENESAS ELECTRONICS CORP(RNECF.US)$ $意法半导体(STM.US)$ Bosch $思佳讯(SWKS.US)$ $高通(QCOM.US)$ $Qorvo(QRVO.US)$
Gapping up
$Moderna(MRNA.US)$
(Shares added 1.6% after the biotech company released its second-quarter results. Despite posting a quarterly loss and drop in revenue, Moderna raised its full-year outlook for its Covid vaccine, its only marketable product.)
$Qorvo(QRVO.US)$
(The stock rallied 6.8% after the company beat analyst expectations on top and bottom lines in the second quarter. Manage...
暂无评论